Nicox SA announced its entry into a research collaboration with Ironwood Pharmaceuticals focused on combining Ironwood’s expertise in soluble guanylate cyclase (sGC) and Nicox’s proprietary nitric oxide (NO)-donating research platform to generate novel compounds in order to identify potential new therapeutics for the treatment of certain ophthalmic conditions.
Under the terms of the research collaboration agreement, each company will be responsible for their own costs associated with activities carried out as part of the collaboration. Depending on the outcome of the research collaboration, Nicox and Ironwood may then enter into discussions regarding Nicox’s further development of any identified product candidate.
“There is evidence to suggest that bringing together Ironwood and Nicox’s respective expertise in sGC and NO-donating compounds can create new treatment options for ophthalmic conditions,” Michael Bergamini, PhD, Executive Vice President, Chief Scientific Officer of Nicox, said in a company news release. “We look forward to working with Ironwood on this exciting collaboration, with the goal of identifying potential new Nicox development pipeline candidates.”